Literature DB >> 16879240

Immunoglobulins and complement factor C4 in adult rhinosinusitis.

M Seppänen1, J Suvilehto, M-L Lokki, I-L Notkola, A Järvinen, H Jarva, I Seppälä, O Tahkokallio, H Malmberg, S Meri, V Valtonen.   

Abstract

We assessed whether complement and its factor C4 or abnormal immunoglobulin levels are associated with chronic or recurrent rhinosinusitis. We used multiple patient and control groups to obtain clinically meaningful data. Adult chronic or recurrent rhinosinusitis and acute purulent rhinosinusitis patients were compared with unselected adults and controls without previous rhinosinusitis. Associated clinical factors were reviewed. Levels of immunoglobulins, plasma C3, C4 and classical pathway haemolytic activity were analysed. C4 immunophenotyping was used to detect C4A and C4B deficiencies as null alleles. Complement was up-regulated in rhinosinusitis. C4A nulls and low IgA, IgG, IgG1, IgG2, IgG3 and IgG4 levels were all more common in chronic or recurrent rhinosinusitis patients than in unselected and healthy controls. We searched for relevant differences between the patient groups. According to stepwise logistic regression analysis, nasal polyposis [odds ratio (OR) 10.64, 95% confidence interval (CI) 2.5-45.7, P = 0.001], bronchial asthma (OR 8.87, 95% CI 2.3-34.9, P = 0.002), C4A null alleles (OR 5.84, 95% CI 1.4-24.9, P = 0.017) and low levels of IgG4 together with either IgG1 or IgG2 (OR 15.25, 95% CI 1.4-166.8, P = 0.026) were more common in chronic or recurrent rhinosinusitis than in acute rhinosinusitis patients. Isolated low IgG subclasses had limited value in patient assessment. C4A null alleles are associated with chronic or recurrent rhinosinusitis, potentially through their effect on immune defence and inflammation control. Multiple clinical and immunological parameters may need to be evaluated when searching for prognostic variables.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16879240      PMCID: PMC1809671          DOI: 10.1111/j.1365-2249.2006.03134.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  53 in total

Review 1.  Complement. First of two parts.

Authors:  M J Walport
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

2.  F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins.

Authors:  Milan Basta; Fredric Van Goor; Stefano Luccioli; Eric M Billings; Alexander O Vortmeyer; Lajos Baranyi; Janos Szebeni; Carl R Alving; Michael C Carroll; Ira Berkower; Stanko S Stojilkovic; Dean D Metcalfe
Journal:  Nat Med       Date:  2003-03-03       Impact factor: 53.440

3.  Diversity in intrinsic strengths of the human complement system: serum C4 protein concentrations correlate with C4 gene size and polygenic variations, hemolytic activities, and body mass index.

Authors:  Yan Yang; Erwin K Chung; Bi Zhou; Carol A Blanchong; C Yung Yu; George Füst; Margit Kovács; Agnes Vatay; Csaba Szalai; István Karádi; Lilian Varga
Journal:  J Immunol       Date:  2003-09-01       Impact factor: 5.422

4.  Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level.

Authors:  Hans U Lutz; Pia Stammler; Valentina Bianchi; Ralph M Trüeb; Thomas Hunziker; Reinhard Burger; Emiliana Jelezarova; Peter J Späth
Journal:  Blood       Date:  2003-09-25       Impact factor: 22.113

5.  Genetic sophistication of human complement components C4A and C4B and RP-C4-CYP21-TNX (RCCX) modules in the major histocompatibility complex.

Authors:  Erwin K Chung; Yan Yang; Robert M Rennebohm; Marja-Liisa Lokki; Gloria C Higgins; Karla N Jones; Bi Zhou; Carol A Blanchong; C Yung Yu
Journal:  Am J Hum Genet       Date:  2002-09-11       Impact factor: 11.025

Review 6.  Complement resistance mechanisms of streptococci.

Authors:  Hanna Jarva; T Sakari Jokiranta; Reinhard Würzner; Seppo Meri
Journal:  Mol Immunol       Date:  2003-09       Impact factor: 4.407

7.  IgG subclass concentrations in certified reference material 470 and reference values for children and adults determined with the binding site reagents.

Authors:  Uwe Schauer; Frank Stemberg; Christian H L Rieger; Michael Borte; Simone Schubert; Frank Riedel; Udo Herz; Harald Renz; Manfred Wick; Hugh D Carr-Smith; Arthur R Bradwell; Wilhelm Herzog
Journal:  Clin Chem       Date:  2003-11       Impact factor: 8.327

8.  IgA deficiency: clinical correlates and responses to pneumococcal vaccine.

Authors:  Eki Edwards; Samiya Razvi; Charlotte Cunningham-Rundles
Journal:  Clin Immunol       Date:  2004-04       Impact factor: 3.969

9.  Prevalence of the chronic sinusitis diagnosis in Olmsted County, Minnesota.

Authors:  Ron G Shashy; Eric J Moore; Amy Weaver
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2004-03

10.  Immunoglobulin deficiencies and susceptibility to infection among homozygotes and heterozygotes for C2 deficiency.

Authors:  Chester A Alper; Jianhua Xu; Katherine Cosmopoulos; Brian Dolinski; Rosanne Stein; Gabriel Uko; Charles E Larsen; Devendra P Dubey; Peter Densen; Lennart Truedsson; Gunnar Sturfelt; Anders G Sjöholm
Journal:  J Clin Immunol       Date:  2003-07       Impact factor: 8.317

View more
  9 in total

1.  Assessment of complement C4 gene copy number using the paralog ratio test.

Authors:  Michelle M A Fernando; Lora Boteva; David L Morris; Bi Zhou; Yee Ling Wu; Marja-Liisa Lokki; Chack Yung Yu; John D Rioux; Edward J Hollox; Timothy J Vyse
Journal:  Hum Mutat       Date:  2010-07       Impact factor: 4.878

2.  ACE gene variants and sarcoidosis in a Finnish population.

Authors:  Elisa Lahtela; Annika Wennerström; Anne Pietinalho; Martin Petrek; Vitezslav Kolek; Marja-Liisa Lokki; Olof Selroos
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

3.  Use of a genetic isolate to identify rare disease variants: C7 on 5p associated with MS.

Authors:  Suvi P Kallio; Eveliina Jakkula; Shaun Purcell; Minna Suvela; Keijo Koivisto; Pentti J Tienari; Irina Elovaara; Tuula Pirttilä; Mauri Reunanen; Denis Bronnikov; Markku Viander; Seppo Meri; Jan Hillert; Frida Lundmark; Hanne F Harbo; Aslaug R Lorentzen; Philip L De Jager; Mark J Daly; David A Hafler; Aarno Palotie; Leena Peltonen; Janna Saarela
Journal:  Hum Mol Genet       Date:  2009-02-16       Impact factor: 6.150

4.  Complement defects in patients with chronic rhinosinusitis.

Authors:  Maria Q Gaunsbaek; Bibi Lange; Anette D Kjeldsen; Viggo Svane-Knudsen; Karsten Skjoedt; Maiken L Henriksen; Christian Nielsen; Yaseelan Palarasah; Soren Hansen
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

5.  Complement C4 deficiency--a plausible risk factor for non-tuberculous mycobacteria (NTM) infection in apparently immunocompetent patients.

Authors:  Hannele Kotilainen; Marja-Liisa Lokki; Riitta Paakkanen; Mikko Seppänen; Pentti Tukiainen; Seppo Meri; Tuija Poussa; Jussi Eskola; Ville Valtonen; Asko Järvinen
Journal:  PLoS One       Date:  2014-03-17       Impact factor: 3.240

6.  Clinical features of patients with homozygous complement C4A or C4B deficiency.

Authors:  Inka Liesmaa; Riitta Paakkanen; Asko Järvinen; Ville Valtonen; Marja-Liisa Lokki
Journal:  PLoS One       Date:  2018-06-21       Impact factor: 3.240

7.  Exome Sequencing Identifies Susceptibility Loci for Sarcoidosis Prognosis.

Authors:  Elisa Lahtela; Matti Kankainen; Juha Sinisalo; Olof Selroos; Marja-Liisa Lokki
Journal:  Front Immunol       Date:  2019-12-24       Impact factor: 7.561

8.  Diversity of extended HLA-DRB1 haplotypes in the Finnish population.

Authors:  Annika Wennerström; Efthymia Vlachopoulou; L Elisa Lahtela; Riitta Paakkanen; Katja T Eronen; Mikko Seppänen; Marja-Liisa Lokki
Journal:  PLoS One       Date:  2013-11-21       Impact factor: 3.240

9.  C3a receptor antagonism as a novel therapeutic target for chronic rhinosinusitis.

Authors:  Jennifer K Mulligan; Kunal Patel; Tucker Williamson; Nicholas Reaves; William Carroll; Sarah E Stephenson; Peng Gao; Richard R Drake; Benjamin A Neely; Stephen Tomlinson; Rodney J Schlosser; Carl Atkinson
Journal:  Mucosal Immunol       Date:  2018-06-15       Impact factor: 7.313

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.